Compare Five9 Inc (FIVN) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Five9 Inc vs Pfizer Inc — how do they compare? Five9 Inc trades at $24.83 (market cap $1.90B), while Pfizer Inc trades at $25.19 (market cap $141.46B). The key difference: Pfizer Inc is far larger — about 74.5× Five9 Inc's market cap, and Pfizer Inc pays a 6.93% dividend while Five9 Inc pays none. Which is the better fit depends on your goals.
| FIVN | PFE | |
|---|---|---|
Market Cap | $1.90B | $141.46B |
Sector | Technology | Health |
52-Week High | $29.16 | $28.56 |
52-Week Low | $13.61 | $23.29 |
Enterprise Value | $1.98B | $192.12B |
Volume | — | 29,869,932 |
Dividend Yield | — | 6.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Five9 (FIVN) trades at $25.58, down 0.89% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $27.00. The company has shown consistent revenue growth, reaching $1.15 billion in 2025, and has beaten earnings estimates for the last three quarters. Recent news highlights include new executive appointments and AI product launches, though some legal scrutiny regarding fiduciary duties exists.
The outlook is positive given strong earnings beats and revenue growth, but risks include high valuation multiples, negative net cash flow, and ongoing legal investigations. Analyst sentiment remains largely bullish, supporting potential upside to the price target.
Pfizer (PFE) trades at $24.25, down 0.94% on the day, with a bearish technical signal from moving averages. The company reported $62.58B in 2025 revenue and a net income margin of 11.83%, with recent quarterly earnings consistently beating expectations. A dividend of $0.43 per share is scheduled for payment on September 1, 2026. The stock's valuation includes a P/E of 18.51 and P/S of 2.19, while analyst consensus price target is $28.25.
Pfizer presents a mixed outlook with stable profitability and a strong dividend, but faces headwinds from patent expirations and competitive pressures. The stock offers value at current levels relative to analyst targets, though technical weakness and revenue declines from peak COVID-era sales pose near-term risks for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Five9 Inc
Five9 provides cloud-native contact center software that enables digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement capabilities, and various software modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's artificial intelligence and automation portfolio supplements and enhances the firm's core CCaaS offerings, including solutions for digital self-service, agent assist technology, and workflow automation. Five9 also offers workforce optimization products that optimize call center efficiency through workforce management solutions, manage interaction quality, and track agent performance.
Read more on FIVN →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
